• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    8/3/22 4:30:00 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KZR alert in real time by email

    Kezar Life Sciences, Inc., (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that, in connection with the previously announced appointment of Nick Mordwinkin, Pharm.D., Ph.D., as the Company's Chief Business Officer, the Compensation Committee of the company's Board of Directors granted Dr. Mordwinkin a nonqualified stock option to purchase 200,000 shares of its common stock with an exercise price of $9.35 per share, which is equal to the closing price of Kezar's common stock on August 1, 2022. In addition, the Compensation Committee of the company's Board of Directors granted one additional employee a nonqualified stock option to purchase 60,000 shares of its common stock with an exercise price of $9.35 per share, which is equal to the closing price of Kezar's common stock on August 1, 2022. The stock options were granted as an inducement award material to the individuals entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The stock options will vest over a four-year period, with 25% of each option vesting on the first anniversary of the employee's start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date. The options are subject to the terms and conditions of Kezar's 2022 Inducement Plan and the stock option agreement covering the grants.

    About Kezar Life Sciences

    Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company's platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005778/en/

    Get the next $KZR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KZR

    DatePrice TargetRatingAnalyst
    8/11/2023$4.00Overweight → Equal Weight
    Wells Fargo
    3/16/2023Outperform → Mkt Perform
    William Blair
    12/8/2021$19.00Overweight
    Wells Fargo
    11/16/2021$12.00 → $20.00Buy
    HC Wainwright & Co.
    7/20/2021$14.00Buy
    JonesTrading
    More analyst ratings

    $KZR
    Financials

    Live finance-specific insights

    See more
    • Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

      Company-hosted conference call and webcast to be held today at 8:00 a.m. ET Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population. In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients. In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared

      3/25/25 7:30:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the "Board") has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC ("Concentra") to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar's development programs or intellectual property. After careful consideration and with the a

      10/17/24 8:35:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT. "The goal of Kezar's R&D Day is to set expectations for 2023, provide updates on our two clinical assets, and highlight the productivity from our Discovery team. We are progressing more quickly than planned with initiating PALIZADE, our next study of zetomipzomib for the treatment of lupus nephritis, and look forward to sharing the details," said John Fowler, Kezar's

      3/13/23 7:00:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Chiang Pichi Luo claimed ownership of 2,975 shares (SEC Form 3)

      3 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

      4/16/25 4:41:19 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider To Zung Phoung

      3 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

      4/16/25 4:39:49 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Schiller Mark C.

      4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

      4/1/25 8:42:03 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Kezar Life Sciences Inc.

      SC 13D - Kezar Life Sciences, Inc. (0001645666) (Subject)

      10/8/24 4:20:17 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kezar Life Sciences Inc.

      SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)

      7/8/24 4:32:39 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kezar Life Sciences Inc. (Amendment)

      SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)

      2/14/24 6:47:29 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kezar Life Sciences downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Kezar Life Sciences from Overweight to Equal Weight and set a new price target of $4.00

      8/11/23 7:45:02 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences downgraded by William Blair

      William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform

      3/16/23 7:29:33 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Kezar Life Sciences with a new price target

      Wells Fargo initiated coverage of Kezar Life Sciences with a rating of Overweight and set a new price target of $19.00

      12/8/21 7:24:52 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Kezar Life Sciences Inc.

      DEFA14A - Kezar Life Sciences, Inc. (0001645666) (Filer)

      4/25/25 4:12:43 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Kezar Life Sciences Inc.

      DEF 14A - Kezar Life Sciences, Inc. (0001645666) (Filer)

      4/25/25 4:10:58 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)

      4/1/25 4:05:51 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

      Company-hosted conference call and webcast to be held today at 8:00 a.m. ET Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population. In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients. In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared

      3/25/25 7:30:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tuesday, March 25, 2025, at 8:00 a.m. ET. The event will highlight topline data from Kezar's PORTOLA trial, a placebo-controlled, randomized, double-blind Phase 2a clinical trial evaluating the efficacy and safety of zetomipzomib in patients with AIH. Additionally, the event will feature presentations from Craig Lammert, MD, Associate Professor of

      3/24/25 8:00:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present at a virtual Key Opinion Leader (KOL) event hosted by William Blair on zetomipzomib clinical development in autoimmune hepatitis (AIH) and will also provide a safety update from the PALIZADE Phase 2b clinical trial in patients with active lupus nephritis (LN) on Thursday, February 27, 2025, at 4:00 p.m. ET. The event will feature Aparna Goel, MD, a general transplant and hepatologist at Stanford University, who will discuss the burden of autoimmune hepatitis (AIH) on patients, curre

      2/18/25 4:01:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Leadership Updates

    Live Leadership Updates

    See more
    • Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

      Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41% Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026 Co-Founder and Board Director, Christopher Kirk, PhD, appointed as Chief Executive Officer   Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs. The strategic realignment

      10/3/23 4:10:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

      Announced positive topline results from the MISSION Phase 2 Trial evaluating zetomipzomib for the treatment of patients with lupus nephritis Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer Cash, cash equivalents and marketable securities totaled $306.8 million as of June 30, 2022 Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2022 and provided a business update. "The second quarter was tremendously productive for Kezar, during which we achieved key clinical milestone

      8/11/22 4:01:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      Kezar Life Sciences, Inc., (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that, in connection with the previously announced appointment of Nick Mordwinkin, Pharm.D., Ph.D., as the Company's Chief Business Officer, the Compensation Committee of the company's Board of Directors granted Dr. Mordwinkin a nonqualified stock option to purchase 200,000 shares of its common stock with an exercise price of $9.35 per share, which is equal to the closing price of Kezar's common stock on August 1, 2022. In addition, the Compensation Committee of the company's Board of Directors granted

      8/3/22 4:30:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care